JP2016509840A5 - - Google Patents

Download PDF

Info

Publication number
JP2016509840A5
JP2016509840A5 JP2015560160A JP2015560160A JP2016509840A5 JP 2016509840 A5 JP2016509840 A5 JP 2016509840A5 JP 2015560160 A JP2015560160 A JP 2015560160A JP 2015560160 A JP2015560160 A JP 2015560160A JP 2016509840 A5 JP2016509840 A5 JP 2016509840A5
Authority
JP
Japan
Prior art keywords
cells
enriched
population
tumor
tim
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015560160A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016509840A (ja
JP6257655B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/038813 external-priority patent/WO2014133568A1/en
Publication of JP2016509840A publication Critical patent/JP2016509840A/ja
Publication of JP2016509840A5 publication Critical patent/JP2016509840A5/ja
Priority to JP2017233698A priority Critical patent/JP6903558B2/ja
Application granted granted Critical
Publication of JP6257655B2 publication Critical patent/JP6257655B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015560160A 2013-03-01 2013-04-30 末梢血から腫瘍反応性t細胞の濃縮された集団を作製する方法 Active JP6257655B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2017233698A JP6903558B2 (ja) 2013-03-01 2017-12-05 末梢血から腫瘍反応性t細胞の濃縮された集団を作製する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361771251P 2013-03-01 2013-03-01
US61/771,251 2013-03-01
PCT/US2013/038813 WO2014133568A1 (en) 2013-03-01 2013-04-30 Methods of producing enriched populations of tumor reactive t cells from peripheral blood

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017233698A Division JP6903558B2 (ja) 2013-03-01 2017-12-05 末梢血から腫瘍反応性t細胞の濃縮された集団を作製する方法

Publications (3)

Publication Number Publication Date
JP2016509840A JP2016509840A (ja) 2016-04-04
JP2016509840A5 true JP2016509840A5 (enExample) 2016-06-23
JP6257655B2 JP6257655B2 (ja) 2018-01-10

Family

ID=48521400

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015560160A Active JP6257655B2 (ja) 2013-03-01 2013-04-30 末梢血から腫瘍反応性t細胞の濃縮された集団を作製する方法
JP2017233698A Active JP6903558B2 (ja) 2013-03-01 2017-12-05 末梢血から腫瘍反応性t細胞の濃縮された集団を作製する方法
JP2019221431A Active JP7029617B2 (ja) 2013-03-01 2019-12-06 末梢血から腫瘍反応性t細胞の濃縮された集団を作製する方法
JP2022011975A Active JP7252383B2 (ja) 2013-03-01 2022-01-28 末梢血から腫瘍反応性t細胞の濃縮された集団を作製する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017233698A Active JP6903558B2 (ja) 2013-03-01 2017-12-05 末梢血から腫瘍反応性t細胞の濃縮された集団を作製する方法
JP2019221431A Active JP7029617B2 (ja) 2013-03-01 2019-12-06 末梢血から腫瘍反応性t細胞の濃縮された集団を作製する方法
JP2022011975A Active JP7252383B2 (ja) 2013-03-01 2022-01-28 末梢血から腫瘍反応性t細胞の濃縮された集団を作製する方法

Country Status (8)

Country Link
US (3) US9844569B2 (enExample)
EP (2) EP3628322A1 (enExample)
JP (4) JP6257655B2 (enExample)
CN (2) CN105163745B (enExample)
AU (4) AU2013379773B2 (enExample)
CA (1) CA2902448C (enExample)
ES (1) ES2771251T3 (enExample)
WO (1) WO2014133568A1 (enExample)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN06624A (enExample) 2005-10-18 2015-07-10 Univ Colorado
US8986702B2 (en) 2008-05-16 2015-03-24 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
DK2966084T3 (en) 2008-08-28 2018-08-06 Taiga Biotechnologies Inc MODULATORS OF MYC, PROCEDURES FOR USING SAME AND PROCEDURES FOR IDENTIFYING SUBSTANCES MODULATING MYC
AU2013292330B2 (en) 2012-07-20 2018-07-12 Htyr Acquisition Llc Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
AU2013379773B2 (en) 2013-03-01 2018-04-19 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor reactive T cells from peripheral blood
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
US20170044496A1 (en) 2014-04-10 2017-02-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
CN107074932A (zh) * 2014-10-02 2017-08-18 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞受体的方法
US10973894B2 (en) 2014-10-02 2021-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
EP4636401A2 (en) 2014-12-19 2025-10-22 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
WO2016179006A1 (en) 2015-05-01 2016-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
CA2986235A1 (en) 2015-05-20 2016-11-24 The Broad Institute, Inc. Shared neoantigens
CN104946589A (zh) * 2015-07-07 2015-09-30 英普乐孚生物技术(上海)有限公司 一种肿瘤特异性til细胞的分离培养方法
US12241053B2 (en) 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
EP3368689B1 (en) 2015-10-28 2020-06-17 The Broad Institute, Inc. Composition for modulating immune responses by use of immune cell gene signature
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
CA3005878A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
GB201522097D0 (en) 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
CN109196094A (zh) * 2016-03-17 2019-01-11 伯克利之光生命科技公司 微流体装置中t淋巴细胞的选择和克隆
MX2019000149A (es) 2016-07-07 2019-09-23 Iovance Biotherapeutics Inc Proteinas de union a ligando 1 de muerte programada 1 (pd-l1) y metodos de uso de las mismas.
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
PL3532607T3 (pl) 2016-10-26 2024-07-01 Iovance Biotherapeutics, Inc. Restymulacja kriokonserwowanych limfocytów naciekających guza nowotworowego
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
WO2018089386A1 (en) 2016-11-11 2018-05-17 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
TWI826360B (zh) 2016-11-17 2023-12-21 美商艾歐凡斯生物治療公司 殘餘腫瘤浸潤性淋巴細胞及製備和使用彼之方法
CN113786476A (zh) 2016-12-02 2021-12-14 泰加生物工艺学公司 纳米颗粒调配物
JP7664020B2 (ja) 2017-01-06 2025-04-17 アイオバンス バイオセラピューティクス,インコーポレイテッド カリウムチャネルアゴニストによる腫瘍浸潤リンパ球の増殖及びその治療的使用
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
US11963966B2 (en) 2017-03-31 2024-04-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
US11913075B2 (en) 2017-04-01 2024-02-27 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
WO2018191558A1 (en) 2017-04-12 2018-10-18 The Broad Institute, Inc. Modulation of epithelial cell differentiation, maintenance and/or function through t cell action, and markers and methods of use thereof
US20200071773A1 (en) 2017-04-12 2020-03-05 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
WO2018209324A2 (en) 2017-05-11 2018-11-15 The Broad Institute, Inc. Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
CN110662762A (zh) 2017-05-24 2020-01-07 诺华股份有限公司 抗体细胞因子移植蛋白和用于治疗癌症的方法
AR112072A1 (es) 2017-06-05 2019-09-18 Iovance Biotherapeutics Inc Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
WO2018232195A1 (en) 2017-06-14 2018-12-20 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
EP3490584B1 (en) 2017-08-03 2021-12-08 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
CN109423478A (zh) * 2017-08-22 2019-03-05 郑州大学第附属医院 一种记忆性t细胞的制备方法
WO2019070755A1 (en) 2017-10-02 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
US11732257B2 (en) 2017-10-23 2023-08-22 Massachusetts Institute Of Technology Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
WO2019094955A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
CN108254557B (zh) * 2017-12-26 2019-05-31 首都医科大学附属北京地坛医院 用cd8阳性的t细胞上pd-1和tigit确定hbv相关原发性肝癌预后的系统
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
KR102956273B1 (ko) 2018-01-08 2026-04-24 이오반스 바이오테라퓨틱스, 인크. 종양 항원-특이적 t-세포에 대해 풍부화된 til 생성물의 생성 방법
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
EP3784254A1 (en) 2018-04-27 2021-03-03 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
TW202039831A (zh) 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 對抗pd-1抗體呈現難治性之非小細胞肺癌(nsclc)病患之治療
CR20210295A (es) 2018-11-05 2021-07-09 Iovance Biotherapeutics Inc Procesos para la producción de linfocitos infiltrantes de tumor y usos de estos en inmunoterapia
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
WO2020186101A1 (en) 2019-03-12 2020-09-17 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
EP3942023A1 (en) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
CN113874033A (zh) 2019-04-08 2021-12-31 泰加生物工艺学公司 用于冷冻保存免疫细胞的组合物和方法
JP2022532608A (ja) 2019-05-14 2022-07-15 タイガ バイオテクノロジーズ,インク. T細胞疲弊を処置するための組成物および方法
CN110452870A (zh) * 2019-05-20 2019-11-15 河南省肿瘤医院 一种肿瘤特异性t细胞的分离培养方法及由其获得的产品
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
WO2021118990A1 (en) 2019-12-11 2021-06-17 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
KR20220119439A (ko) 2019-12-20 2022-08-29 인스틸 바이오 유케이 리미티드 종양 침윤 림프구를 분리하기 위한 장치 및 방법 및 그것의 용도
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
EP4121513A1 (en) * 2020-03-20 2023-01-25 The United States of America, as represented by the Secretary, Department of Health and Human Services Methods of isolating t cells and t-cell receptors from peripheral blood by single-cell analysis for immunotherapy
JP2020143057A (ja) * 2020-04-01 2020-09-10 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するt細胞受容体を単離する方法
JP2023524639A (ja) 2020-04-22 2023-06-13 アイオバンス バイオセラピューティクス,インコーポレイテッド 患者特異的免疫療法用細胞の製造調整システム及び調整方法
CN111850119B (zh) * 2020-06-04 2022-08-26 吴式琇 定量检测bst1、stab1和tlr4基因表达水平的方法及应用
EP4225330A1 (en) 2020-10-06 2023-08-16 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
RU2752973C1 (ru) * 2020-10-12 2021-08-11 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" Способ определения качественных параметров иммуносупрессивных клеток у онкологических пациентов
CN112266899A (zh) * 2020-10-26 2021-01-26 北京卡替医疗技术有限公司 修饰的免疫细胞及其用途
WO2022204564A2 (en) 2021-03-25 2022-09-29 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
IL311570A (en) 2021-10-14 2024-05-01 Arsenal Biosciences Inc Immune cells with common expression chain and logic gate systems
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229115A (en) 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
US5656465A (en) 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
ATE374244T1 (de) 2000-02-11 2007-10-15 Dana Farber Cancer Inst Inc Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
DE10232697A1 (de) 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US20040250305A1 (en) 2002-09-09 2004-12-09 Latif Zuhair A. Adoptive transfer and uses thereof
DE60334250D1 (de) 2003-05-08 2010-10-28 Life Technologies Corp Erzeugung und isolierung antigenspezifischer t-zellen
WO2007018198A1 (ja) * 2005-08-09 2007-02-15 Kumamoto University Hla-a2陽性者用hsp105由来癌拒絶抗原ペプチド及びこれを含む医薬
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
KR101586617B1 (ko) * 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 pd-1에 대한 항체
US9416165B2 (en) * 2007-10-26 2016-08-16 The Regents Of The University Of California Methods of inhibiting viral replication and improving T cell function employing soluble Tim-3 inhibitors
ES2666667T3 (es) * 2008-01-29 2018-05-07 Fred Hutchinson Cancer Research Center Identificación de células T CD8+ que son CD161 hi y/o IL-18R (alfa) hi y tienen una capacidad de evacuación rápida de fármacos
AU2009210221B2 (en) 2008-01-31 2014-06-26 Bayer Cropscience Aktiengesellschaft The use of alternan as ingredient for certain foodstuffs
WO2010006808A1 (en) 2008-07-18 2010-01-21 Sentoclone Ab Composition comprising in vitro expanded t-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer
CN101625361A (zh) 2009-02-26 2010-01-13 中国人民解放军第二军医大学 一种慢性乙型肝炎患者免疫状态的诊断方法
US8741642B2 (en) * 2010-10-22 2014-06-03 Virginia Commonwealth University Methods for producing autologous immune cells resistant to myeloid-derived suppressor cells effects
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
CN102935228B (zh) * 2011-08-15 2015-02-18 苏州丁孚靶点生物技术有限公司 用于肿瘤治疗的试剂、其用途及方法
JP2014020930A (ja) 2012-07-18 2014-02-03 Kanazawa Univ 膵癌診断及び治療効果予測判定バイオマーカー
AU2013379773B2 (en) * 2013-03-01 2018-04-19 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor reactive T cells from peripheral blood
CN104371974B (zh) 2014-10-24 2017-03-22 杭州阿诺生物医药科技股份有限公司 一种自体外周血淋巴细胞cik的培养方法
CN105754990A (zh) 2016-01-29 2016-07-13 深圳精准医疗科技有限公司 一种pd-1/ctla-4双特异性抗体的制备方法及其应用
CR20200608A (es) 2016-04-21 2021-01-20 Immatics Biotechnologies Gmbh INMUNOTERAPIA CONTRA EL MELANOMA Y OTROS TIPOS DE CÁNCER (Divisional 2018-0551)
CN106177931B (zh) 2016-08-25 2018-02-02 河北浓孚雨生物科技有限公司 免疫检测点双阻断ctl高效率杀伤细胞制剂的制备方法
CN106957905B (zh) 2016-12-23 2020-12-04 孙涛 一种用于评估肿瘤免疫治疗效果的分子检测方法及引物组合物及试剂盒
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
RU2662916C1 (ru) 2017-06-05 2018-07-31 Общество с ограниченной ответственностью "Альтернативные Инновационные Технологии" Способ терапии метастатического рака с использованием вируса Сендай
EP3647433B1 (en) 2017-06-30 2023-04-12 Osaka University Method for predicting effect of tumor immunotherapy using tumor cytotoxic activity of peripheral blood t cells as index
CN108254557B (zh) 2017-12-26 2019-05-31 首都医科大学附属北京地坛医院 用cd8阳性的t细胞上pd-1和tigit确定hbv相关原发性肝癌预后的系统

Similar Documents

Publication Publication Date Title
JP2016509839A5 (enExample)
Fang et al. Advances in NK cell production
JP7440027B2 (ja) 多能性幹細胞から免疫細胞療法用t細胞を誘導する方法
RU2015138483A (ru) Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток
CN104321425B (zh) 用于诱导和扩增源自外周血单个核细胞的自然杀伤细胞的方法
Granzin et al. Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy
JP2012521215A5 (enExample)
JP2022130607A (ja) 養子免疫療法における免疫細胞調節のための組成物および方法
CN107002039B (zh) 使用t细胞用于培养自然杀伤细胞的方法
Tresoldi et al. Stability of human rapamycin-expanded CD4+ CD25+ T regulatory cells
CN108473959B (zh) 用来在过继性免疫疗法中进行免疫细胞调节的组合物和方法
CN111757745B (zh) 产生天然杀伤细胞的方法和用于治疗癌症的组合物
Bonanno et al. Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures
JP2016539929A5 (enExample)
JP6775426B2 (ja) 臍帯血由来のプールnk細胞並びにがん及び慢性感染症の治療のためのこれらの用途
Lu et al. DNA methyltransferase inhibitor promotes human CD4+ CD25hFOXP3+ regulatory T lymphocyte induction under suboptimal TCR stimulation
JP5118624B2 (ja) 新規なヒトt細胞集団
JP2023501381A (ja) Stem細胞からのキメラ抗原受容体修飾t細胞の作製とその治療的使用
US20220226379A1 (en) Dnmt3a knock-out stat5 activated genetically engineered t-cells
Chavez et al. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity
JP2013537187A5 (enExample)
EP3170895A1 (en) Production method for pluripotent stem cells having antigen-specific t cell receptor gene
CN107002036A (zh) 用于建立具有编码抗原特异性t细胞受体的基因的多能性干细胞的方法
Hosseini et al. Ex vivo expansion of CD3depleted cord blood-MNCs in the presence of bone marrow stromal cells; an appropriate strategy to provide functional NK cells applicable for cellular therapy
Peragine et al. Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients